Skip to main content
SpringerLink
Log in

Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma

  • Day-to-Day Practice
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Thymoma and thymic carcinoma are rare neoplasms of the mediastinum, arising from the epithelial cells of the thymus. While surgical resection is the treatment of choice in early stages, platin-based chemotherapy is mainly used in patients with advanced or metastatic disease; however, the prognosis is poor. Here we present the case of a 54 year old female patient suffering from a CD117-negative thymic carcinoma with widespread metastases. After several courses of different kinds of chemotherapy, finally these approaches failed to be effective. Thus we initiated a treatment with sorafenib, an inhibitor of several receptor tyrosine kinases. The treatment was tolerated very well, and within a few weeks the general condition of the patient improved significantly. A CT-scan, performed 3 months after therapy with sorafenib started, showed a 50 % reduction of tumor size, and this effect lasted for 15 months. When the carcinoma relapsed again, we administered another course of chemotherapy and, because of lacking success, we even tried to use sunitinib. However, the patient died in a septic shock, based on progressive disease. In summary, we present a patient with metastastic thymic carcinoma, in which sorafenib led to a tumor-control for 18 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Engels EA (2010) Epidemiology of thymoma and associated malignancies. J Thorac Oncol 5(Suppl 4):S260–S265

    Article  PubMed  Google Scholar 

  2. Kim DJ, Yang WI, Choi SS et al (2005) Prognostic and clinical relevance of the World Health Organization schema for the classification of thymic epithelial tumors: a clinicopathologic study of 108 patients and literature review. Chest 127:755–761

    Article  PubMed  Google Scholar 

  3. Okumura M, Ohta M, Tateyama H, Nakagawa K, Matsumura A, Maeda H, Tada H, Eimoto T, Matsuda H, Masaoka A (2002) The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 94:624–632

    Article  PubMed  Google Scholar 

  4. Strobel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, Gold R, Semik M, Kiefer R, Nix W, Schalke B, Müller-Hermelink HK, Marx A (2004) Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 22:1501–1509

    Article  PubMed  Google Scholar 

  5. Gadalla SM, Rajan A, Pfeiffer R, Kristinsson SY, Björkholm M, Landgren O, Giaccone G (2011) A population-based assessment of mortality and morbidity patterns among patients with thymoma. Int J Cancer 128:2688–2694

    Article  PubMed  CAS  Google Scholar 

  6. Masaoka A, Monden Y, Nakahara K, Tanioka T (1981) Follow-up study of thymomas with special reference to their clinical stages. Cancer 48:2485–2492

    Article  PubMed  CAS  Google Scholar 

  7. Chen G, Marx A, Chen WH, Yong J, Puppe B, Stroebel P, Mueller-Hermelink HK (2002) New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 95:420–429

    Article  PubMed  Google Scholar 

  8. Davenport E, Malthaner RA (2008) The role of surgery in the management of thymoma: a systematic review. Ann Thorac Surg 86:673–684

    Article  PubMed  Google Scholar 

  9. Venuta F, Rendina EA, Longo F, De Giacomo T, Anile M, Mercadante E, Ventura L, Osti MF, Francioni F, Coloni GF (2003) Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg 76:1866–1872

    Article  PubMed  Google Scholar 

  10. Huang J, Rizk NP, Travis WD, Seshan VE, Bains MS, Dycoco J, Downey RJ, Flores RM, Park BJ, Rusch VW (2007) Feasibility of multimodality therapy including extended resections in stage IVA thymoma. J Thorac Cardiovasc Surg 134:1477–1483

    Article  PubMed  Google Scholar 

  11. Loehrer PJ Sr, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR Jr, Livingston R, Johnson DH (2001) Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 91:2010–2015

    Article  PubMed  CAS  Google Scholar 

  12. Schmitt J, Loehrer PJ Sr (2010) The role of chemotherapy in advanced thymoma. J Thorac Oncol 5(10 Suppl 4):S357–S360

    Article  PubMed  Google Scholar 

  13. Rajan A, Giaccone G (2010) Targeted therapy for advanced thymic tumors. J Thorac Oncol 5(10 Suppl 4):S361–S364

    Article  PubMed  Google Scholar 

  14. Loehrer PJ, Yiannoutsos CT, Dropcho S et al (2006) A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma (abstract #7079). J Clin Oncol 24:383s

    Article  Google Scholar 

  15. Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, Loehrer PJ Sr (2011) Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 29:2060–2065

    Article  PubMed  CAS  Google Scholar 

  16. Strobel P, Hohenberger P, Marx A (2010) Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J Thorac Oncol 5(10 Suppl 4):S286–S290

    Article  PubMed  Google Scholar 

  17. Suzuki E, Sasaki H, Kawano O, Endo K, Haneda H, Yukiue H, Kobayashi Y, Yano M, Fujii Y (2006) Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 36:351–356

    Article  PubMed  Google Scholar 

  18. Henley JD, Cummings OW, Loehrer PJ Sr (2004) Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 130:222–224

    Article  PubMed  CAS  Google Scholar 

  19. Farina G, Garassino MC, Gambacorta M, La Verde N, Gherardi G, Scanni A (2007) Response of thymoma to cetuximab. Lancet Oncol 8:449–450

    Article  PubMed  Google Scholar 

  20. Palmieri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M, Montella L (2007) Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci 12:757–761

    Article  PubMed  CAS  Google Scholar 

  21. Kurup A, Burns M, Dropcho S, Pao W, Loehrer PJ (2005) Phase II study of gefitinib treatment in advanced thymic malignancies (abstract #7068). J Clin Oncol 23:16s

    Google Scholar 

  22. Bedano P, Perkins S, Burns M et al. (2008) A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma (abstract #19087). J Clin Oncol 26s

  23. Pan CC, Chen PC, Chiang H (2004) KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 202:375–381

    Article  PubMed  CAS  Google Scholar 

  24. Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC (2009) Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol 10:1270–1273

    Article  Google Scholar 

  25. Strobel P, Hartmann M, Jakob A, Mikesch K, Brink I, Dirnhofer S, Marx A (2004) Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 350:2625–2626

    Article  PubMed  Google Scholar 

  26. Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TR, DeBono JS (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14:804–810

    Article  PubMed  CAS  Google Scholar 

  27. Rajan A, Giaccone G (2011) Chemotherapy for thymic tumors: induction, consolidation, palliation. Thorac Surg Clin 21:107–114

    Article  PubMed  Google Scholar 

  28. Cimpean AM, Raica M, Encica S, Cornea R, Bocan V (2008) Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat 190:238–245

    Article  PubMed  Google Scholar 

  29. Tomita M, Matsuzaki Y, Edagawa M, Maeda M, Shimizu T, Hara M, Onitsuka T (2002) Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J Thorac Cardiovasc Surg 124:493–498

    Article  PubMed  Google Scholar 

  30. Strobel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou-Strauss A, Strauss L, Sauer C, Mayer F, Hohenberger P, Marx A (2010) Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 103:196–200

    Article  PubMed  CAS  Google Scholar 

  31. Bisagni G, Rossi G, Cavazza A, Sartori G, Gardini G, Boni C (2009) Long lasting response to the multikinase inhibitor bay 43–9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 4:773–775

    Article  PubMed  Google Scholar 

  32. Li XF, Chen Q, Huang WX, Ye YB (2009) Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol 26:157–160

    Article  PubMed  Google Scholar 

  33. Dişel U, Oztuzcu S, Beşen AA, Karadeniz C, Köse F, Sümbül AT, Sezer A, Nursal GN, Abalı H, Ozyılkan O (2011) Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer 71:109–112

    Article  PubMed  Google Scholar 

  34. Cimpean AM, Ceauşu R, Encică S, Gaje PN, Ribatti D, Raica M (2011) Platelet-derived growth factor and platelet-derived growth factor receptor-α expression in the normal human thymus and thymoma. Int J Exp Pathol 92:340–344

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

The support by Dr. Thomas Hess, radiologist, and Dr. Christian Gustmann, pathologist, is greatly appreciated.

Conflict of Interest Statement

Both authors declare, that there are no relationships, conditions or circumstances presenting a potential conflict of interest.

Author information

Authors and Affiliations

  1. St. Vincenz-Hospital, Limburg, Germany

    Thomas Neuhaus & Joachim Luyken

  2. St. Vincenz-Krankenhaus, Auf dem Schafsberg, 65549, Limburg, Germany

    Thomas Neuhaus

Authors
  1. Thomas Neuhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joachim Luyken
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Neuhaus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neuhaus, T., Luyken, J. Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma. Targ Oncol 7, 247–251 (2012). https://doi.org/10.1007/s11523-012-0235-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-012-0235-8

Keywords

Search

Navigation